LONDON, Nov. 2, 2017 /PRNewswire/ -- Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Download the full report: https://www.reportbuyer.com/product/5139387Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.The global idiopathic pulmonary fibrosis market generated $1,616 million in 2016, and is projected to reach $3,569 million by 2023, registering a CAGR of 11.9% during the study period. The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug and region. According to type of drug, the market is divided into pirfenidone and nintedanib. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.KEY BENEFITS FOR STAKEHOLDERSThe report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors.This report provides an extensive analysis of the current and emerging market trends and dynamics in the market from 2016 to 2023 that helps identify the upcoming market opportunities.Recent industry trends and developments and the future opportunities are also covered.Extensive knowledge about the key market players and their strategies is provided.Comprehensive analysis of the various factors that drive and restrain the growth of the market is provided.Key Market SegmentsBy Type of DrugPirfenidoneNintedanibBy RegionNorth AmericaU.S.CanadaMexicoEuropeFranceGermanyUKItalySpainRest of EuropeAsia-PacificJapanChinaIndiaSouth KoreaRest of Asia-PacificLAMEABrazilSaudi ArabiaSouth AfricaRest of LAMEAKey market playersThe key players operating in this market includeMediciNova, Inc.Boehringer IngelheimF. Hoffmann-La RocheFibroGen, Inc.Promedior, Inc.Merck & Co., Inc.Galapagos NVBiogenBristol-Myers Squibb CompanyPrometic Life Sciences Inc.Cipla Inc.Download the full report: https://www.reportbuyer.com/product/5139387 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
Advertisement
Download the full report: https://www.reportbuyer.com/product/5139387Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.The global idiopathic pulmonary fibrosis market generated $1,616 million in 2016, and is projected to reach $3,569 million by 2023, registering a CAGR of 11.9% during the study period. The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug and region. According to type of drug, the market is divided into pirfenidone and nintedanib. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.KEY BENEFITS FOR STAKEHOLDERSThe report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors.This report provides an extensive analysis of the current and emerging market trends and dynamics in the market from 2016 to 2023 that helps identify the upcoming market opportunities.Recent industry trends and developments and the future opportunities are also covered.Extensive knowledge about the key market players and their strategies is provided.Comprehensive analysis of the various factors that drive and restrain the growth of the market is provided.Key Market SegmentsBy Type of DrugPirfenidoneNintedanibBy RegionNorth AmericaU.S.CanadaMexicoEuropeFranceGermanyUKItalySpainRest of EuropeAsia-PacificJapanChinaIndiaSouth KoreaRest of Asia-PacificLAMEABrazilSaudi ArabiaSouth AfricaRest of LAMEAKey market playersThe key players operating in this market includeMediciNova, Inc.Boehringer IngelheimF. Hoffmann-La RocheFibroGen, Inc.Promedior, Inc.Merck & Co., Inc.Galapagos NVBiogenBristol-Myers Squibb CompanyPrometic Life Sciences Inc.Cipla Inc.Download the full report: https://www.reportbuyer.com/product/5139387 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/idiopathic-pulmonary-fibrosis-market---global-opportunity-analysis-and-industry-forecast-2017-2023-300549109.html
SOURCE ReportBuyer
